Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) EBITDA: 2014-2025

Historic EBITDA for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to -$90.2 million.

  • Viking Therapeutics' EBITDA fell 329.01% to -$90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$238.7 million, marking a year-over-year decrease of 147.02%. This contributed to the annual value of -$110.4 million for FY2024, which is 29.56% down from last year.
  • Latest data reveals that Viking Therapeutics reported EBITDA of -$90.2 million as of Q3 2025, which was down 37.76% from -$65.5 million recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' EBITDA ranged from a high of -$12.7 million in Q4 2021 and a low of -$90.2 million during Q3 2025.
  • Its 3-year average for EBITDA is -$36.0 million, with a median of -$24.1 million in 2023.
  • Its EBITDA has fluctuated over the past 5 years, first climbed by 6.09% in 2024, then plummeted by 329.01% in 2025.
  • Over the past 5 years, Viking Therapeutics' EBITDA (Quarterly) stood at -$12.7 million in 2021, then plummeted by 48.41% to -$18.9 million in 2022, then fell by 27.46% to -$24.1 million in 2023, then tumbled by 57.07% to -$37.8 million in 2024, then plummeted by 329.01% to -$90.2 million in 2025.
  • Its last three reported values are -$90.2 million in Q3 2025, -$65.5 million for Q2 2025, and -$45.1 million during Q1 2025.